Superior Retinal Gene Transfer and Biodistribution Profile of Subretinal Versus Intravitreal Delivery of AAV8 in Nonhuman Primates
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Purpose: To investigate shedding and biodistribution characteristics of recombinant adeno-associated virus serotype 8 (rAAV8) after single-dose subretinal or intravitreal injection in nonhuman primates (NHP, Macaca fascicularis) as a surrogate for environmental hazard and patient safety. Methods: In a study for regulatory submission, 22 NHP were divided into four cohorts receiving either single subretinal injections of vehicle or clinical grade rAAV8 (1 × 1011 or 1 × 1012 vector genomes [vg]) versus single intravitreal application of 1 × 1012 vg. Viral shedding and biodistribution were monitored in biofluids for up to 91 days, followed by necropsy and tissue harvesting of all major organs, the visual pathway, and lymphatic tissue. Quantification of vector genomes was done by quantitative (q)PCR. Results: Shedding occurred in a dose-dependent manner in all biofluids and persisted for a maximum of 7 days. Intravitreal delivery led to increased and persistent (up to 13 weeks) distribution of vector genomes in blood and draining lymphatic tissue, increased off-target deposition, and inefficient gene transfer to the retina. No vector targeting of the germ line was observed in any cohort. Conclusions: These data illustrate that subretinal application of rAAV8 leads to a more favorable biodistribution profile compared to intravitreal injections. Extraocular biodistribution is limited after subretinal delivery, while intravitreal injection leads to both greater and more persistent systemic exposure, evident in blood and lymphatic tissues. With the knowledge on the dynamics of shedding in a setting mimicking clinical application, guidelines can be developed to refine clinical trial protocols to reduce the risk for trial subjects and their environment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the vitreous space, there are higher chances of exposure to systemic circulation,15 whereas the subretinal space does not expose AAV to systemic circulation, owing to the blood-retina barrier.9,33”
From Systemic and local immune responses to intraocular AAV vector administration in non-human primates (2022) · cites this paper as [15]
In the citing paper
“It has been shown that intravitreal injection results in the increased spreading of AAV particles into systemic circulation leading to adaptive responses.15”
From Systemic and local immune responses to intraocular AAV vector administration in non-human primates (2022) · cites this paper as [15]
In the citing paper
“AAV particles can be found in draining lymphoid tissues following injection in the eye (Seitz et al., 2017), where the adaptive immune response is primed.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Seitz et al., 2017
In the citing paper
“A previous study showed that IVT injection of AAV8 leads to more persistent systemic exposure than subretinal injection (Seitz et al., 2017).”
From AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery (2023) · cites this paper as Seitz et al., 2017
In the citing paper
“These higher doses may trigger a stronger immune response and increase titres of neutralising antibodies [257,258,259], which can spread through the blood and lymphatic tissues [260] and potentially lead to reduced transduction efficacy and a lack of transgene expression with repeated administration [261,262].”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [260]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273 · cited 1×
“This is evident from clinical trials, where much higher dosages of rAAV8 were delivered primarily into the systemic circulation without causing serious adverse events.(20) However, these trials have shown that systemic exposure to significant numbers of any rAAV serotype can induce humoral and cellular immune response…”
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“However, these trials have shown that systemic exposure to significant numbers of any rAAV serotype can induce humoral and cellular immune response followed by directed removal of successfully transduced target cells by cytotoxic T lymphocytes.(21) Previous studies in large animal models have demonstrated that rAAV8 g…”
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
A Multifunctional AAV-CRISPR-Cas9 and Its Host Response
Chew, W. L., Tabebordbar, M., Cheng, J. K. W., Mali, P., Wu, E. Y., Ng, A. H. M., Zhu, K., Wagers, A. J., & Church, G. M. (2016) · Nature Methods · doi:10.1038/nmeth.3993 · Cited by 617 · cited 1×
“, CRISPR-Cas9) to edit genomic DNA with less than 100% specificity, off-target transduction may be more of a concern.(38)”
Don’t edit the human germ line
Lanphier, E., Urnov, F., Haecker, S. E., Werner, M., & Smolenski, J. (2015) · Nature · doi:10.1038/519410a · Cited by 530 · cited 1×
“One important component of patient safety is avoidance of germ line transduction.(13,14) There was no vector presence in the germ line, regardless of sex, vector dosage, or route of administration.”
Kohl, S., Marx, T., Giddings, I., Jägle, H., Jacobson, S. G., Apfelstedt-Sylla, E., Zrenner, E., Sharpe, L. T., & Wissinger, B. (1998) · Nature Genetics · doi:10.1038/935 · Cited by 340
Self-citationThe cone dysfunction syndromes: Table 1
Aboshiha, J., Dubis, A. M., Carroll, J., Hardcastle, A. J., & Michaelides, M. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-306505 · Cited by 314 · cited 1×
“Affected individuals suffer pronounced photopic defects such as total color blindness, reduced visual acuity, hemeralopia (day blindness), nystagmus, and photophobia.(3) To date, six genes have been identified that link to ACHM.”
Kohl, S. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.14.2107 · Cited by 299
Nathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y. C., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G. D., & Davidoff, A. M. (2007) · Blood · doi:10.1182/blood-2006-03-010181 · Cited by 272
Mutations in the Cone Photoreceptor G-Protein α-Subunit Gene GNAT2 in Patients with Achromatopsia
Kohl, S., Baumann, B., Rosenberg, T., Kellner, U., Lorenz, B., Vadalà, M., Jacobson, S. G., & Wissinger, B. (2002) · The American Journal of Human Genetics · doi:10.1086/341835 · Cited by 265
Self-citationDosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey
Vandenberghe, L. H., Bell, P., Maguire, A. M., Cearley, C. N., Xiao, R., Calcedo, R., Wang, L., Castle, M. J., Maguire, A. C., Grant, R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002103 · Cited by 242
Genetic basis of total colourblindness among the Pingelapese islanders
Sundin, O. H., Yang, J.-M., Li, Y., Zhu, D., Hurd, J. N., Mitchell, T. N., Silva, E. D., & Maumenee, I. H. (2000) · Nature Genetics · doi:10.1038/77162 · Cited by 241 · cited 1×
“The prevalence is greater in certain genetically isolated areas like the Micronesian atoll Pingelap, where up to 6% of the population are affected by the condition.(2) ACHM is a congenital disease that exclusively impairs cone function.”
Michalakis, S., Mühlfriedel, R., Tanimoto, N., Krishnamoorthy, V., Koch, S., Fischer, M. D., Becirovic, E., Bai, L., Huber, G., Beck, S. C., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.149 · Cited by 185 · cited 1×
“It contained a cone-arrestin 3 promoter driving CNGA3 expression that has been shown to have therapeutic effect in the Cnga3 / mouse model.(12) GMP grade cis and trans plasmid DNA was provided by Aldevron (Fargo, ND, USA) using a highquality characterized Escherichia coli master cell bank (MCB), and Atlantic BioGMP (N…”
Self-citationCronin, T., Vandenberghe, L. H., Hantz, P., Juttner, J., Reimann, A., Kacsó, Á., Huckfeldt, R. M., Busskamp, V., Kohler, H., Lagali, P. S., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404077 · Cited by 184
A Nonsense Mutation in PDE6H Causes Autosomal-Recessive Incomplete Achromatopsia
Kohl, S., Coppieters, F., Meire, F., Schaich, S., Roosing, S., Brennenstuhl, C., Bolz, S., van Genderen, M. M., Riemslag, F. C. C., Lukowski, R., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.07.006 · Cited by 180
Self-citationThe Ethics of Germline Gene Editing
Gyngell, C., Douglas, T., & Savulescu, J. (2017) · Journal of Applied Philosophy · doi:10.1111/japp.12249 · Cited by 174 · cited 1×
“One important component of patient safety is avoidance of germ line transduction.(13,14) There was no vector presence in the germ line, regardless of sex, vector dosage, or route of administration.”
Kotterman, M. A., Yin, L., Strazzeri, J. M., Flannery, J. G., Merigan, W. H., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2014.115 · Cited by 169 · cited 5×
“The observation that mesenteric lymph nodes, which do not drain from the injection site, did show a similar degree of vector deposition as deep cervical, retropharyngeal, and mandibular lymph nodes, also supports the notion of circulation-mediated biodistribution after IVT.”
InfluentialTargeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors
Kay, C. N., Ryals, R. C., Aslanidi, G. V., Min, S. H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D., Ayala, A. E., Van Vliet, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062097 · Cited by 168
Preclinical safety evaluation of AAV2-sFLT01— a gene therapy for age-related macular degeneration
MacLachlan, T. K., Lukason, M., Collins, M., Munger, R., Isenberger, E., Rogers, C., Malatos, S., DuFresne, E., Morris, J., Calcedo, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.258 · Cited by 166 · cited 2×
“Such a systemic visibility after IVT may promote vector recognition by the immune system and might help to explain any form of immune response after gene therapy.(11,18,19) Recent findings complement this hypothesis by showing a qualitative difference in immune response after IVT.”
Castle, M. J., Gershenson, Z. T., Giles, A. R., Holzbaur, E. L. F., & Wolfe, J. H. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.189 · Cited by 154 · cited 1×
“Our data are in line with these reports and show that dose and route of application are important determinants of the extent of this distribution pattern.(27) While our data do not explain the mechanism of transduction along the visual pathway, they clearly show that both routes of application can lead to anterograde…”
Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina
Ramachandran, P. S., Lee, V., Wei, Z., Song, J. Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J. I. W., Aleman, T. S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.111 · Cited by 147
Ehlers, J. P., Kaiser, P. K., & Srivastava, S. K. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305294 · Cited by 131
Takahashi, K., Igarashi, T., Miyake, K., Kobayashi, M., Yaguchi, C., Iijima, O., Yamazaki, Y., Katakai, Y., Miyake, N., Kameya, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.008 · Cited by 99
Provost, N., Le Meur, G., Weber, M., Mendes-Madeira, A., Podevin, G., Cherel, Y., Colle, M.-A., Deschamps, J.-Y., Moullier, P., & Rolling, F. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.022 · Cited by 87 · cited 1×
“Previous studies in large animal models have demonstrated that rAAV8 gene therapy has a favorable safety profle(22) and efficiently transduces photoreceptors,(23,24) and that vector genome can be found along the visual pathway after subretinal delivery of rAAV.(25,26) Our data are in line with these reports and show t…”
Mutation of ATF6 causes autosomal recessive achromatopsia
Ansar, M., Santos‐Cortez, R. L. P., Saqib, M. A. N., Zulfiqar, F., Lee, K., Ashraf, N. M., Ullah, E., Wang, X., Sajid, S., Khan, F. S., et al. (2015) · Human Genetics · doi:10.1007/s00439-015-1571-4 · Cited by 83 · cited 1×
“It encodes a protein that is part of the unfolded protein response in the endoplasmic reticulum.(9) At the University Eye Hospital Tübingen, we performed the first clinical gene therapy for ACHM caused by mutations in CNGA3 using subretinal administration of rAAV8.”
Stieger, K., Colle, M.-A., Dubreil, L., Mendes-Madeira, A., Weber, M., Le Meur, G., Deschamps, J. Y., Provost, N., Nivard, D., Cherel, Y., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.41 · Cited by 75 · cited 1×
“Previous studies in large animal models have demonstrated that rAAV8 gene therapy has a favorable safety profle(22) and efficiently transduces photoreceptors,(23,24) and that vector genome can be found along the visual pathway after subretinal delivery of rAAV.(25,26) Our data are in line with these reports and show t…”
Grau, T., Artemyev, N. O., Rosenberg, T., Dollfus, H., Haugen, O. H., Cumhur Sener, E., Jurklies, B., Andreasson, S., Kernstock, C., Larsen, M., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq517 · Cited by 72
Self-citationKhabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A., Sahel, J., & Dalkara, D. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.26031 · Cited by 71
Ye, G.-J., Budzynski, E., Sonnentag, P., Nork, T. M., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Smith, L. M., Arndt, T., Calcedo, R., et al. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.164 · Cited by 64 · cited 1×
“Such a systemic visibility after IVT may promote vector recognition by the immune system and might help to explain any form of immune response after gene therapy.(11,18,19) Recent findings complement this hypothesis by showing a qualitative difference in immune response after IVT.”
Evaluation of an optimized injection system for retinal gene therapy in human patients
Fischer, M. D., Hickey, D. G., Singh, M. S., & MacLaren, R. E. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.086 · Cited by 61
Self-citationWoodard, K. T., Liang, K. J., Bennett, W. C., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.01568-16 · Cited by 59
Stability and Safety of an AAV Vector for Treating RPGR-ORF15 X-Linked Retinitis Pigmentosa
Deng, W.-T., Dyka, F. M., Dinculescu, A., Li, J., Zhu, P., Chiodo, V. A., Boye, S. L., Conlon, T. J., Erger, K., Cossette, T., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.035 · Cited by 55 · cited 1×
“In line with other reports, vector biodistribution and consequent deposition in internal organs were minimal in the subretinal cohorts.(15) Both dose (1Eþ11 vs.”
Combined Rod and Cone Transduction by Adeno-Associated Virus 2/8
Manfredi, A., Marrocco, E., Puppo, A., Cesi, G., Sommella, A., Della Corte, M., Rossi, S., Giunti, M., Craft, C. M., Bacci, M. L., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.154 · Cited by 43
Total colour blindness: an introduction
Sharpe, L. T., & Nordby, K. S. (1990) · Cited by 35
Da Costa, R., Röger, C., Segelken, J., Barben, M., Grimm, C., & Neidhardt, J. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19701 · Cited by 32
Tarantal, A. F., Lee, C. C. I., Martinez, M. L., Asokan, A., & Samulski, R. J. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.130 · Cited by 32
Marangoni, D., Wu, Z., Wiley, H. E., Zeiss, C. J., Vijayasarathy, C., Zeng, Y., Hiriyanna, S., Bush, R. A., Wei, L. L., Colosi, P., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.067 · Cited by 29 · cited 1×
“Such a systemic visibility after IVT may promote vector recognition by the immune system and might help to explain any form of immune response after gene therapy.(11,18,19) Recent findings complement this hypothesis by showing a qualitative difference in immune response after IVT.”
Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals
Ru, Q., Li, W., Wang, X., Zhang, S., Chen, L., Zhang, Y., Ge, Y. C., Zu, Y., Liu, Y., & Zheng, D. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.12 · Cited by 6 · cited 1×
“Taken together, this evidence suggests a biodistribution profile not unlike what is described for intramuscular and intravenous injections.(16,17) Such a systemic visibility after IVT may promote vector recognition by the immune system and might help to explain any form of immune response after gene therapy.”
Cited by
Cukras, C., Wiley, H. E., Jeffrey, B. G., Sen, H. N., Turriff, A., Zeng, Y., Vijayasarathy, C., Marangoni, D., Ziccardi, L., Kjellstrom, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.025 · Cited by 268
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Self-citationClinical Perspective: Treating RPE65-Associated Retinal Dystrophy
Maguire, A. M., Bennett, J., Aleman, E. M., Leroy, B. P., & Aleman, T. S. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.029 · Cited by 184
Fischer, M. D., Michalakis, S., Wilhelm, B., Zobor, D., Muehlfriedel, R., Kohl, S., Weisschuh, N., Ochakovski, G. A., Klein, R., Schoen, C., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.1032 · Cited by 177
Self-citationYiu, G., Chung, S. H., Mollhoff, I. N., Nguyen, U. T., Thomasy, S. M., Yoo, J., Taraborelli, D., & Noronha, G. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.002 · Cited by 153
Metadata
- Authors
- Seitz, I. P., Michalakis, S., Wilhelm, B., Reichel, F. F., Ochakovski, G. A., Zrenner, E., Ueffing, M., Biel, M., Wissinger, B., Bartz-Schmidt, K. U., Peters, T., Fischer, M. D., & for the RD-CURE Consortium
- Affiliations
- University of Tübingen (DE)
- Center for Integrated Protein Science Munich (DE)
- STZ eyetrial (DE)
- University Eye Hospital, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
- University of Oxford (GB)
- Corresponding author
- Peters, Tobias
- ORCID
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2017-11-08
- Volume
- 58
- Issue
- 13
- Pages
- 5792
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2736625713
- Cited by
- 108
- References
- 38
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 15 · 2023: 15 · 2022: 9 · 2021: 12 · 2020: 15 · 2019: 5 · 2018: 10
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- intravitreal injection, viral shedding, tissue distribution, non-human primates, Macaca fascicularis, lymphoid tissue
- MeSH terms
- Dependovirus, Animals, Dose-Response Relationship, Drug, Female, Genetic Vectors, Macaca fascicularis, Male, Recombinant Proteins, Retina, Retinal Diseases, Tissue Distribution, Genetic Therapy, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.